Overview

A Study to Evaluate the Safety and Tolerability of Raxibacumab in Healthy Subjects

Status:
Completed
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety and tolerability of raxibacumab in healthy subjects.
Phase:
Phase 3
Details
Lead Sponsor:
Human Genome Sciences Inc.
Human Genome Sciences Inc., a GSK Company
Collaborators:
Emergent BioSolutions
GlaxoSmithKline
Treatments:
Antibodies, Monoclonal